Mike began his academic career in 2007 after nearly ten years working in early stage drug discovery at Pfizer, Inc (Groton and Cambridge Laboratories). While at Pfizer, he worked on a variety of programs across therapeutic areas, focusing mostly on gene family-targeted medicinal chemistry (phosphodiesterases, G-protein coupled receptors, and kinases). He has a strong interest in technology-enabled medicinal chemistry and synthesis, employing green chemistry, parallel synthesis, flow chemistry, and cheminformatics as a means to accelerate the drug discovery process and reduce costs. With that in mind, his last three years at Pfizer-Cambridge was spent leading a chemical technology lab that collaborated with research sites across the Pfizer enterprise to establish best methods for higher-throughput drug discovery.